Quantcast
Last updated on April 20, 2014 at 13:20 EDT

Latest Pneumococcal conjugate vaccine Stories

2009-07-20 11:00:00

MADISON, N.J., July 20 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that its stockholders overwhelmingly approved the adoption of its merger agreement with Pfizer (NYSE: PFE) at Wyeth's Annual Meeting of Stockholders. Based on a preliminary vote count by Wyeth's transfer agent, over 98 percent of shares voted favored the merger. Approval of the merger agreement required an affirmative vote of the majority of outstanding shares. Commenting on the transaction, Bernard...

2009-07-14 07:00:00

COLLEGEVILLE, Pa., July 14 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the Chilean Ministry of Health, MINSAL (Ministerio de Salud), has become the first government agency to approve Prevenar 13* Valent, (Pneumococcal Conjugate Vaccine 13 Valent (Diphtheria CRM(197) Protein)) for infants and young children. Prevenar 13 Valent is approved for active immunization of children aged 6 weeks through 5 years for the prevention of invasive...

27fdacf7cef9734d090fa2c825da2d551
2009-07-09 11:40:00

The World Health Organization (WHO) has now approved a new cervical cancer vaccine from pharmaceutical company GlaxoSmithKline (GSK), which means that U.N. agencies and partners can now officially buy millions of doses of the vaccine for poor countries worldwide. GSK stated Thursday that the approval would help expedite the accessibility of Cervarix globally. Gardasil, the rival vaccine made by pharmaceutical company Merck & Co., was the first cervical cancer vaccine to be approved by...

2009-07-08 07:37:21

Infants who received two or three primary doses of the 7-valent pneumococcal conjugate vaccine (PCV-7) both had a decreased rate of carrying pneumococcal microorganisms that can cause pneumonia and other infections, compared to infants who were not vaccinated, according to a study in the July 8 issue of JAMA.Crowded infant vaccine schedules and less favorable cost-effectiveness calculations have prompted exploration of reduced-dose vaccine schedules other than the currently recommended...

5cb8c8d217db08f3a07e4f9a0cc14d461
2009-06-13 06:50:00

The Bill & Melinda Gates Foundation and the governments of Britain, Italy, Canada, Russia and Norway announced a $1.5 billion initiative on Friday to provide poor nations better access to vaccines against pneumococcal disease such as meningitis and pneumonia. The Advance Market Commitment program creates financial incentive with a guaranteed price to entice companies to make the substantial investments required to develop new vaccines. The Geneva-based GAVI Alliance, the Gates-funded...

2009-06-12 11:33:22

A $1.5 billion plan to save the world's poorest children from pneumococcal diseases was activated Friday in Lecce, Italy, international aid groups said. Representatives of five countries and four international aid groups officially made good on commitments promised in 2007 to speed delivery of pneumococcal vaccines that kill 1.6 million people year, including an estimated 1 million children under age 5. Italy donated $635 million, Britain $485 million, Canada $200 million, Russia $80 million,...

2009-06-11 06:00:00

COLLEGEVILLE, Pa., June 11 /PRNewswire-FirstCall/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most prevalent serotypes associated with pneumococcal disease (PD), the leading cause of vaccine-preventable death in children younger than five worldwide. The Phase 3 data presented...

2009-06-04 15:05:00

WASHINGTON, June 4 /PRNewswire-USNewswire/ -- The U.S. Agency for International Development (USAID) yesterday contributed $75 million to improve and expand children's immunization programs in developing countries. The contribution is part of the overall U.S. commitment to global health and the new global health initiative, a 6-year, $63 billion dollar effort announced by President Obama in May. The grant was announced by Deputy Secretary of State Jacob Lew at the Global Alliance for...

2009-05-07 14:23:00

WAYNE, Pa., May 7 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that Professor Hanna Nohynek, M.D., Ph.D. has been appointed Head Consultant of Encorium's clinical vaccine research team. Dr. Nohynek has an impressive track record in...

2009-05-07 07:00:00

-- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease -- COLLEGEVILLE, Pa., May 7 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) granted priority review to the company's Biologic License Application (BLA) for Prevnar 13*, Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM(197) Protein), which was submitted on March 31....